

**AMENDMENT TRANSMITTAL LETTER (Large Entity)**Applicant(s): **Cockerill et al.**

Docket No.

**PU3743USW**

Application No.

**10/030,527**

Filing Date

**1/9/02**

Examiner

**Bruck Kifle**

Customer No.

**23347**

Group Art Unit

**1624**

Confirmation No.

**4128**Invention: **ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS****COMMISSIONER FOR PATENTS:**

Transmitted herewith is an amendment in the above-identified application.


The fee has been calculated and is transmitted as shown below.

**CLAIMS AS AMENDED**

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	30 -	32 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0	x \$88.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>

- ☒ No additional fee is required for amendment.
- ☐ Please charge Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_
- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☐ Payment by credit card. Form PTO-2038.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

  
Signature

John L. Lemanowicz, Reg. No. 37,388  
Attorney for Applicants  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8247  
Facsimile: (919) 483-7988

Dated: **2/10/05**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:

P11LARGE/REV09



FEB 10 2005 3:22PM GLAXO WELLCOME  
Atty. Docket No.: PUS743USV

NO. 6425 P. 5

**BEST AVAILABLE COPY**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Cockerill et al

Serial No.: 10/030,527

Filing Date: January 9, 2002

For: ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS

Examiner: B. Kifle

Art Unit: 1624

Box Issue fee  
Commissioner for Patents  
Washington D.C. 20231

**AMENDMENT UNDER 37 C.F.R. 1.312**

Sir:

This paper is filed, after receipt of Notice of Allowance, under 37 C.F.R. 1.312 to correct an error in the claims.

Please amend the above-identified application as follows:

**Amendments to the Claims** begin on page 2 of this paper.

**Remarks** begin on page 7 of this paper.